RT Journal Article
SR Electronic
T1 Predicting the effect of statins on cancer risk using genetic variants: a Mendelian randomization study in UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.28.20028902
DO 10.1101/2020.02.28.20028902
A1 Paul Carter
A1 Mathew Vithayathil
A1 Siddhartha Kar
A1 Rahul Potluri
A1 Amy M. Mason
A1 Susanna C. Larsson
A1 Stephen Burgess
YR 2020
UL http://medrxiv.org/content/early/2020/02/29/2020.02.28.20028902.abstract
AB Laboratory studies have suggested oncogenic roles of lipids, as well as anticarcinogenic effects of statins. We here assess the potential effect of statin therapy on cancer risk in Mendelian randomization analyses. We obtained genetic associations with the risk of overall and 22 site-specific cancers for 367,703 individuals in UK Biobank. In total, 75,037 individuals had a cancer event. Variants in the HMGCR gene region, which represent proxies for statin treatment, were associated with overall cancer risk (OR per 1 standard deviation increase in LDL-cholesterol 1.32, 95% CI 1.13-1.53, p=0.0003), but variants in gene regions representing alternative lipid-lowering treatment targets (PCSK9, LDLR, NPC1L1, APOC3, LPL) were not. Genetically-predicted LDL-cholesterol was not associated with overall cancer risk (OR 1.01, 95% CI 0.98-1.05, p=0.50). Our results predict that statins reduce cancer risk, but other lipid-lowering treatments do not. This suggests that statins reduce cancer risk through a cholesterol independent pathway.Competing Interest StatementThe authors have declared no competing interest.Funding StatementStephen Burgess is supported by Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number 204623/Z/16/Z). Stephen Burgess and Amy Mason are supported by the UK National Institute for Health Research Cambridge Biomedical Research Centre.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the manuscript is publicly available or else available to any bona fide researcher on application. http://lipidgenetics.org/#data-downloads-title https://biobank.ctsu.ox.ac.uk/crystal/